The iShares MSCI USA Quality Factor ETF (QUAL) was launched on 07/16/2013, and is a smart beta exchange traded fund designed to offer broad exposure to the Style Box - All Cap Blend category of the market.What Are Smart Beta ETFs?For a long time now, the ETF industry has been flooded with products based on market capitalization weighted indexes, which are designed to represent the broader market or a particular market segment.Investors who believe in market efficiency should consider market cap indexes, as ...

A smart beta exchange traded fund, the Franklin U.S. Equity Index ETF (USPX) debuted on 06/01/2016, and offers broad exposure to the Style Box - All Cap Blend category of the market.What Are Smart Beta ETFs?The ETF industry has traditionally been dominated by products based on market capitalization weighted indexes that are designed to represent the market or a particular segment of the market.A good option for investors who believe in market efficiency, market cap weighted indexes offer a low-cost, conveni ...

Core Insights - The current economic environment favors well-capitalized and growth-oriented companies, which are outperforming their counterparts in the U.S. market [1] - A structural shift in the U.S. market is indicated by the sustained outperformance of large-cap and growth securities over small-cap and value stocks [2] - The S&P 500 Growth Index has returned 15.46% over the past year, significantly outperforming the S&P 500 Value Index, which gained 8.85% [3] - Barclays maintains a positive outlook on U.S. growth stocks due to strong earnings momentum and lower leverage risk associated with large-cap securities [4] Market Sentiment - Bank of America and Goldman Sachs have raised their year-end forecasts for the S&P 500, with BofA increasing its target to 6,300 and Goldman to 6,600, reflecting a bullish sentiment [5] - Citigroup, Barclays, and Deutsche Bank have also raised their year-end targets for the S&P 500, indicating growing optimism in the U.S. equity market [6] - The S&P 500 has gained approximately 6.7% year-to-date, with a significant rally following a pause on tariffs announced by President Trump [6] Investment Opportunities - Large-cap ETFs are recommended for investors seeking exposure to the improving market outlook, particularly in the tech sector driven by the AI boom [7] - Notable large-cap ETFs include Vanguard S&P 500 ETF (VOO), SPDR S&P 500 ETF Trust (SPY), and iShares Core S&P 500 ETF (IVV), with VOO having the largest asset base of $689.85 billion [8] - Growth-focused ETFs such as Vanguard Growth ETF (VUG) and iShares Russell 1000 Growth ETF (IWF) are highlighted for investors looking to capitalize on the shift in market sentiment [11][12] - VUG has an asset base of $175.61 billion, making it the largest among growth-focused options, with annual fees of 0.04% for SPYG, VUG, and IUSG, suitable for long-term investing [13]

Core Viewpoint - The company reported a decline in revenue and net profit for 2024, primarily due to high base effects from 2023 and adjustments in the respiratory therapy business, while showing growth in certain segments in Q1 2025 [1][2]. Financial Performance - For 2024, the company achieved revenue of 7.566 billion yuan (-5.09%), net profit attributable to shareholders of 1.806 billion yuan (-24.63%), and operating cash flow of 1.816 billion yuan (-14.61%) [1]. - In Q1 2025, the company reported revenue of 2.436 billion yuan (+9.18%), net profit of 625 million yuan (-5.26%), and operating cash flow of 658 million yuan (+2.64%) [1][2]. Business Segment Analysis - The respiratory therapy segment generated revenue of 2.597 billion yuan, with certain products experiencing declines due to high base effects, while home respiratory devices and nebulizers showed growth [2]. - The blood glucose management and POCT business achieved revenue of 1.03 billion yuan (+40.21%), with significant growth in CGM products [2]. - The home health measurement segment reported revenue of 1.564 billion yuan (-0.41%), with some products declining due to high base effects, while others like electronic blood pressure monitors saw double-digit growth [2]. - The clinical and rehabilitation business generated revenue of 2.093 billion yuan (+0.24%), with good growth trends in acupuncture needles and wheelchairs, but a decline in infection control products due to demand fluctuations [2]. - The emergency business reported revenue of 239 million yuan (+34.05%), with self-developed AED products achieving certification and further technical upgrades [2]. Strategic Initiatives - The company made a strategic investment of $27.21 million in Inogen, acquiring a 9.9% stake, to expand its market presence in Europe and the US, leveraging Inogen's established production bases and market share [3]. - The partnership with Inogen will focus on distribution cooperation for various respiratory products and aims to enhance product exports and collaborative R&D efforts [3]. Dividend Policy - In 2024, the company distributed a total dividend of 802 million yuan, representing 44.40% of net profit attributable to shareholders, reflecting a strong commitment to investor returns and long-term confidence [3]. Investment Outlook - The company is positioned as a leader in home medical devices, focusing on respiratory and oxygen therapy, blood glucose management, and infection control, with an improving product structure and brand advantages [4]. - Forecasts for net profit from 2025 to 2027 are adjusted to 2.341 billion yuan, 2.699 billion yuan, and 3.104 billion yuan, reflecting year-on-year growth of 29.63%, 15.29%, and 15.03% respectively [4].

本文来自彭博终端，终端用户可运行DOCV RES SUS6NADWX2PS 阅读原文。非终端用户可点击文末 "阅读原文" 预约演示。 彭博行业研究（Bloomberg Intelligence）就各公司、行业和市场提供全球投研分析以及交互 式数据。BI对ETF的研究覆盖全球市场，以深度、前沿、独特的视角为您展现ETF市场趋势， 分析热门课题，分享专业洞见。 本期主题： 看空但做多：2025年ETF投资者的表现 （彭博行业研究）——尽管年景艰难且美国新关税政策冲击市场，但我们预计大多数ETF投 资者将继续定期定额投资热门ETF，即便他们越来越看空。不过，一些投资者似乎已经通过 在投资组合中增加黄金或现金ETF来进行对冲。 无论看涨还是看跌 ETF投资者都倾向于长期持有 对大量买入并持有的ETF投资者而言，尽管"解放日"以及贸易冲突带来冲击，他们仍料将继 续 定期定额投资VOO和IVV这种"低成本b e t a "基金的惯例。美国上市ETF今年吸纳的3 , 0 0 0 亿美元资金中，仅这两只ETF就占了2 0%。其他吸引大量现金流入的股票ETF还包括VTI和 SPLG。 不过，流入现金和黄金ETF的资金增加表明投 ...

美国ETF市场在2024年势不可挡。资金流量和新发行量均创下纪录新高。资产管理规模突破了10万亿美 元大关。加密货币相关ETF引爆全场。主动管理型ETF人气飙升。加杠杆的单只股票ETF吸引了惊人的资 金流量，其中专注于美国微策略（MicroStrategy）软件公司的多只ETF出现了运作异常。一只ETF竟然能 从一家已完全变成比特币杠杆游戏的古早软件企业的波动中获利？了不起的2024年。 虽然ETF市场的增长主要来自常见因素——低成本的贝塔策略产品和少数战术型产品，但更新颖且风险更 高的产品吸引了大量资金流入，也占据了大量媒体头条。结果是：投资者及顾问们感到不堪重负和困惑不 已。 点击图片查看大图 ETF的增长既快速又稳定，这得益于ETF这种投资工具的实用性和灵活性。 如下图所示，2024年是ETF发行的标志性一年，共有757只新ETF进入市场，令基金总数增至3,934只。基 金关闭率维持在正常范围的较低水平。 点击图片查看大图 无论以何指标计量，是ETF数量、资金流量还是资产管理规模，2024年美国ETF行业都堪称热火朝天。 2024年美国ETF资金流量 股票和固定收益这两种规模最大的ETF资产类别也在20 ...